Core Insights - Bionano Genomics showcased advancements in optical genome mapping (OGM) during Symposium 2026, emphasizing its potential for scaling up to thousands of samples per year through automation and advanced software solutions [1][2][10] Group 1: Symposium Highlights - The event attracted over 1,250 registrants and featured 35 speakers, highlighting the community's engagement and the advancements in OGM technology [2] - Dr. Alexander Hoischen from Radboud University Medical Center emphasized 2026 as a pivotal year for scaling OGM, aiming to process 3,000 samples annually, up from 500 in 2025 [3] - Dr. Chantal Courtemanche presented a protocol for purifying DNA and RNA from FFPE samples using Bionano's Ionic system, which enhances the quality of next-generation sequencing (NGS) assays [4] Group 2: Technological Innovations - Dr. Vineet Bafna introduced a computational tool called OMKar for generating digital karyotypes from complex chromosomal rearrangements, which could enhance future software developments [5] - Dr. Brandon Shaw demonstrated how VIA software supports the analysis of OGM data, facilitating consistent assessments of structural variants in hematologic malignancies [6][7] - Dr. Adam Smith discussed the scalability of OGM, noting that it could process up to 10,000 samples per year, significantly outperforming long-read sequencing systems in terms of throughput and cost [10] Group 3: Community and Future Directions - The International OGM Consortium (ICOGM) was introduced to foster collaborative research efforts in OGM [11] - The final day of the symposium concluded with discussions on best practices for OGM implementation and future research directions in cytogenomics and molecular pathology [12] - Bionano's leadership highlighted the transformative role of OGM in advancing cytogenomics and molecular pathology, reinforcing the community's commitment to innovation [15][17]

TABLE OF CONTENTS As filed with the Securities and Exchange Commission on September 11, 2025. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Bionano Genomics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Bionano Genomics, Inc. 9540 Towne Centre Drive, Suite 100 San Diego, California 921 ...